York Clinical Research Facility


The Clinical Research Facility (CRF) is a joint venture, utilising the expertise and resources of the University of York and the York Hospital. Based at the hospital, the unit aims to provide an environment that can deliver early phase trials and support basic scientific research, which will result in high impact results.

The facility began life in 2009 as the Experimental Medicines Unit (EMU) with a change in identity coming in 2013 to reflect the closer ties with the University’s Centre for Immunology and Infection and increasing support to basic and translational research.
The CRF has recently committed to delivering a tissue bank, following the University of York’s acquisition of a Human Tissue Authority research license. This initiative will develop networks with the clinical care teams and help provide researchers from both the Hospital and University with access to human tissue for basic and translational research.


  • Prof. Charles Lacey- Clinical Director
  • Wasif Rashid- Facility Coordinator
  • Steven Pollock- Tissue Bank Manager
  • Nelisa Poshai- Research Nurse
  • Nicola Marshall- Research Nurse
  • Kay Kell- Research Nurse
  • Dr Rebecca Wiggins- Senior Research Techinician
  • David Thompson- Clinical Trials Assistant


  • LEISH1- A Phase 1 First in Human study to assess the safety and immunogenicity of a new Leishmania vaccine candidate ChAd63-KH
  • NCRN464- A commercial randomised, double-blind, placebo-controlled, Phase I/II Trial of RNActive®-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory Prostate Cancer.
  • ADON- A commercial 48-week, double-blind, randomized, multi-centre, parallel-group study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fingolimod in patients with acute de-myelinating optic neuritis.
  • DAPIDAR- A randomised, double blind phase I study to assess the safety, pharmacokinetics and pharmacodynamics of single and 14 days dosing with two vaginal microbicide formulations containing either Darunavir, or Dapivirine plus Darunavir.

Links and Documents

York Clinical Research Facility